Ann MacDougall Net Worth

The estimated Net Worth of Ann L. Mac Dougall is at least 541 千$ dollars as of 13 May 2022. Ms. Dougall owns over 3,000 units of Opiant Pharmaceuticals Inc stock worth over 540,596$ and over the last 5 years she sold OPNT stock worth over 0$. In addition, she makes 0$ as Director at Opiant Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. MacDougall OPNT stock SEC Form 4 insiders trading

Ann has made over 5 trades of the Opiant Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 3,000 units of OPNT stock worth 32,790$ on 13 May 2022.

The largest trade she's ever made was exercising 15,993 units of Opiant Pharmaceuticals Inc stock on 15 March 2021 worth over 159,930$. On average, Ann trades about 2,410 units every 68 days since 2019. As of 13 May 2022 she still owns at least 26,179 units of Opiant Pharmaceuticals Inc stock.

You can see the complete history of Ms. Dougall stock trades at the bottom of the page.

Ann MacDougall biography

Ann L. MacDougall is Director of the Company. She has extensive global experience spanning both operating and legal roles for both private and non-profit organizations. Since January 2014, she has served as President of Encore.org, a national organization building a movement for individuals developing second careers in public or non-profit service. From 2007 to December 2013, Ms. MacDougall was Chief Operating Officer of Acumen, an investment fund focused on goods and services for low-income customers. Prior to Acumen, she had a long career managing legal matters at PriceWaterhouseCoopers, including as General Counsel in the U.S. and Deputy General Counsel based in Paris. Ms. MacDougall earned her B.A. at Tufts University and her J.D. at Brooklyn Law School.

Insiders trading at Opiant Pharmaceuticals Inc

Over the last 21 years, insiders at Opiant Pharmaceuticals Inc have traded over 16,027,532$ worth of Opiant Pharmaceuticals Inc stock and bought 199,545 units worth 2,080,156$ . The most active insiders traders include Craig A Collard、Marc A Cohen、Alain J Cohen. On average, Opiant Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of 159,046$. The most recent stock trade was executed by Roger Crystal on 27 January 2023, trading 1,358 units of OPNT stock currently worth 27,513$.

What does Opiant Pharmaceuticals Inc do?

Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

Complete history of Ms. Dougall stock trades at Progenics Pharmaceuticals、Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals Inc executives and stock owners

Opiant Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Roger Crystal,
  President, Chief Executive Officer, Director
• Michael Sinclair,
  Executive Chairman of the Board
• Dr. Roger Crystal,
  Pres, CEO & Director
• Dr. Phil Skolnick D.Sc. (hon), Ph.D.,
  Chief Scientific Officer
• David D. O'Toole,
  Chief Financial Officer
• Michael Porter,
  IR Contact Officer
• Richard Daly,
  Independent Director
• Craig Collard,
  Independent Director
• Thomas Thomas,
  Director
• Gabrielle Silver,
  Director
• Ann MacDougall,
  Director
• Aziz Mottiwala,
  Chief Commercial Officer
• Rahsaan Thompson,
  General Counsel
• Phil Skolnick,
  Chief Scientific Officer
• Arvind Agrawal,
  Executive Vice President - Medical Affairs
• David O'Toole,
  Chief Financial Officer
• Matthew R. Ruth,
  Chief Commercial Officer
• Dr. Mark Heath Ellison Ph.D.,
  Chief Devel. Officer
• Brian Gorman,
  EVP Corp. Devel. & Gen. Counsel
• Ben Atkins,
  VP of Communications & Investor Relations
• Matthew R. Ruth,
  Chief Commercial Officer
• Ronald W Kaiser,
  Director
• Melvin Iii Wesley,
  Chief Financial Officer
• William F Stasior,
  Director
• Steven G Finn,
  Director
• Joseph W Kuhn,
  VP & Chief Financial Officer
• Alain J Cohen,
  President & Chief Tech Officer
• Marc A Cohen,
  Chairman, CEO, Treas, & Sec
• Brian Gorman,
  
• Mark Jason Heath Ellison,
  Chief Development Officer
• Masuoka K. Lorianne,
  Director